Shares of Enzon Pharmaceuticals (ENZN [1]) shot up on the news that Pfizer may be interested in inking a deal with the company. Last year, Enzon sold a manufacturing plant and four marketed products for $300 million in cash to Italy's sigma-tau Group. That left the developer free to focus on its pipeline, which includes metastatic breast cancer drug PEG-SN38. The company recently began Phase II trials of that drug. Its pipeline also includes two Phase I oncology drugs, as well as Oncaspar, which is in Phase I for solid tumors and lymphomas. Neither Enzon nor Pfizer were available to comment on the rumor, according to the Forbes report.
- take a look at this item [2]
Related Articles:
Enzon to focus on pipeline following $327M asset sale [3]
Enzon won't spin off biotech division after all [4]
Enzon may concentrate on novel drugs [5]
Enzon spins off biotech ops into $150M enterprise [6]
Links:
[1] http://finapps.forbes.com/finapps/jsp/finance/compinfo/CIAtAGlance.jsp?tkr=ENZN
[2] http://www.forbes.com/2010/01/13/enzon-pfizer-shares-markets-equities-rumor.html
[3] http://www.fiercebiotech.com/story/enzon-focus-pipeline-following-327m-asset-sale/2009-11-09
[4] http://www.fiercebiotech.com/story/enzon-wont-spin-biotech-division-after-all/2008-12-02
[5] http://www.fiercebiotech.com/story/enzon-ponders-option-concentrate-novel-drugs/2008-08-11
[6] http://www.fiercebiotech.com/story/enzon-spins-off-biotech-ops-into-150m-enterprise/2008-05-07